Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience

Marta Riva, Lara Crucitti, Emanuele Ravano, MD, Michele Nichelatti, PhD, Gianluigi Reda, MD, Cristina Fiamenghi, Roberto Cairoli, Alfredo Molteni, MD

Blood (2018) 132 (Supplement 1): 4375.

https://doi.org/10.1182/blood-2018-99-115283

Published: 2018

Journal Articles

Refining Hellström-Lindberg Score: Which Patients Could Benefit from Standard Dose EPO?

Marta Riva, MD, Gianluigi Reda, MD, Emanuele Ravano, MD, Ramona Cassin, MD, Mariarita Sciumè, MD, Pierangelo Spedini, MD, Giambattista Bertani, MD, Michele Nichelatti, PhD, Agostino Cortelezzi, Prof, Roberto Cairoli, MD, Alfredo Molteni, MD

Blood (2017) 130 (Supplement 1): 2981.

https://doi.org/10.1182/blood.V130.Suppl_1.2981.2981

Published: 2017

Journal Articles

The Immunohistochemical Expression of p53 in Bone Marrow Biopsy Has Unfavorable Prognostic Impact in Higher Risk Myelodysplastic Syndromes If It Is at Least 10%

Alfredo Molteni, MD, Emanuele Ravano, MD, Laura Bandiera, MD, Marta Riva, MD, Michele Nichelatti, Silvia Cantoni, MD, Mauro Truini, MD, Roberto Cairoli, MD

Blood (2016) 128 (22): 5546.

https://doi.org/10.1182/blood.V128.22.5546.5546

Published: 2016

Journal Articles

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Patrizia Zappasodi, MD, Laura Marbello, MD, Erika Borlenghi, MD, Monica Fumagalli, MD, Massimo Bernardi, MD, Nicola Stefano Fracchiolla, MD, Matteo Da Vià, MD, Marianna Rossi, MD, Emanuele Ravano, MD, Elisa Cerqui, MD, Virginia Valeria Ferretti, PhD, Mario Cazzola, Prof, Carlo Castagnola, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 3740.

https://doi.org/10.1182/blood.V126.23.3740.3740

Published: 2015

Journal Articles

Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL)

Erika Borlenghi, MD, Chiara Pagani, MD, Claudia Basilico, MD, Massimo Bernardi, MD, Nicola Fracchiolla, MD, Francesca Guidotti, MD, Laura Marbello, MD, Andrea Ferrario, MD, Carlo Messina, MD, Emanuele Ravano, MD, Cinzia Lamorgese, Marta Petullà, Giuseppe Rossi, MD

Blood (2014) 124 (21): 279.

https://doi.org/10.1182/blood.V124.21.279.279

Published: 2014

Journal Articles

Danazol Treatment in Lower Risk MDS Patient with Severe Thrombocytopenia: A Monocentric Experience

Alfredo Molteni, Marta Riva, Emanuele Ravano, MD, Rosa Greco, Enrica Morra

Blood (2014) 124 (21): 5615.

https://doi.org/10.1182/blood.V124.21.5615.5615

Published: 2014

NARROW

Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience

Refining Hellström-Lindberg Score: Which Patients Could Benefit from Standard Dose EPO?

The Immunohistochemical Expression of p53 in Bone Marrow Biopsy Has Unfavorable Prognostic Impact in Higher Risk Myelodysplastic Syndromes If It Is at Least 10%

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL)

Danazol Treatment in Lower Risk MDS Patient with Severe Thrombocytopenia: A Monocentric Experience

Email alerts

ASH Publications

American Society of Hematology

Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience

Refining Hellström-Lindberg Score: Which Patients Could Benefit from Standard Dose EPO?

The Immunohistochemical Expression of p53 in Bone Marrow Biopsy Has Unfavorable Prognostic Impact in Higher Risk Myelodysplastic Syndromes If It Is at Least 10%

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL)

Danazol Treatment in Lower Risk MDS Patient with Severe Thrombocytopenia: A Monocentric Experience

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only